Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...

Quantum Strategy's David Roche says Europe's defense spending needs to increase by at least $200 billion as he discusses the ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Former Walton Family Enterprises CEO expands BanyanGlobal’s family office capabilities as the preeminent advisor to owners of ...

Posay, the dermatologist-recommended leader in skincare, is thrilled to announce its partnership with the BNP Paribas Open as ...

Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

The value that laboratories contribute to clinical decision-making is critical to the future of health care and enables ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...